Canada markets open in 5 hours 2 minutes

Arch Biopartners Inc. (ACHFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.5600+0.0200 (+1.30%)
At close: 10:29AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.5400
Open1.5600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.5600 - 1.5600
52 Week Range1.4730 - 3.3800
Volume2,100
Avg. Volume6,121
Market Cap97.342M
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

    TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that Arch is receiving advisory services and up to $4,000,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) to support the research and development of the LSALT peptide (Metablok) progra

  • GlobeNewswire

    Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

    TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an Arch scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and

  • GlobeNewswire

    Shares for Interest Debt Settlement; Grants Options

    TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $201,459 in interest accrued up to September 30, 2022 on all five of the deferred convertible notes outstanding and disclosed in the Company’s financial statements (the “Notes”). The shares for debt settlement is pending final approval from the TSX Venture Exchange (T